Epratuzumab is an investigational agent for the treatment of lupus. The researchers hoped to learn whether epratuzumab could be a safe and effective treatment for people with moderate-to-severe lupus.
There are a number of treatments used for lupus nephritis, but none of them are approved by the U.S. Food and Drug Administration (FDA). The researchers hoped to compare the efficacy and safety of MMF and azathioprine as maintenance therapy.
The researchers hoped to learn whether treatment with belimumab could reduce the use of steroids in people with active lupus.
The researchers hoped to learn whether there are any tests that could predict low blood sugar in women with lupus taking hydroxychloroquine.
The researchers hoped to learn whether a lupus damage questionnaire, filled out by lupus patients instead of their doctors, would be accurate and/or useful.
The researchers hoped to learn what factors have an impact on how much time it takes for a lupus patient to develop skin damage.
The researchers hoped to determine the risk of developing blood clots in people with lupus, while factoring in the year of diagnosis and disease severity.
The researchers hoped to determine whether umbilical cord stem cells could be given safely to people with severe and treatment-resistant lupus, and whether this might help to treat lupus.